Research workbench
Human LTC4 synthase in complex with product analogs - implications for enzyme catalysis
Analyse Human LTC4 synthase in complex with product analogs - implications for enzyme… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.
- PDB
- 4JRZ
- Type
- protein
- Length
- 155 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Leukotriene C4 synthase
- EC
- 4.4.1.20
- UniProt
- Q16873
- Ligands
- PLM, PAM, GTX, NI, SO4
Structure
x-ray diffraction · 1 distinct chain · 79% helix, 0% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Leukotriene C4 synthase (EC 4.4.1.20) | protein | 155 | 79% helix, 0% strand | Q16873 |
Ligands and binding sites
- PLM · Palmitic acid · ligand · 5 copies · chains A
- PAM · Palmitoleic acid · ligand · chains A
- GTX · S-hexylglutathione · ligand · chains A
- NI · Nickel (II) ion · metal · 3 copies · chains A
- SO4 · Sulfate ion · ion · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Compared structures
- 4JRZ · Human LTC4 synthase in complex with product analogs - implications for enzyme catalysis · the same entry in another collection · chain A against A, TM-score 1.00
- Q16873 · AlphaFold monomer V2.0 prediction for leukotriene C4 synthase (Q16873) · a predicted model of the same protein · chain A against A, TM-score 0.94
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q16873
- Elsewhere: RCSB PDB 4JRZ · PDBe 4JRZ · UniProt Q16873
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.